
Instilling Hope for Life After Lymphoma
Dr. Manali Kamdar’s unique and empathetic approach to patient care and lymphoma research leaves a lasting impact on the lymphoma community.

Dr. Manali Kamdar’s unique and empathetic approach to patient care and lymphoma research leaves a lasting impact on the lymphoma community.

Former Pharmaceutical Executive Joins Lymphoma Research Foundation Board of Directors

Established through the generosity of the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing LRF’s unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.
The tenth anniversary of the Lymphoma Research Foundation’s Blood Cancer Awareness Month initiative expected to reach millions.

Foundation to Celebrate Achievements of Honorees AstraZeneca, Thomas M. Habermann, MD and Heroes Among the Lymphoma Community

A multi-stakeholder working group recommends consistent biomarker, genetic and genomic testing terminology for patient education and clinical care.

LRF celebrates 25 years of innovation and progress with global awareness and fundraising campaign.

Projects awarded from this year’s class of CDA and Postdoctoral Fellows include early clinical trials of novel therapies, investigations into the biology of Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, and new mechanisms
for chimeric antigen receptor (CAR) T cell therapy.

Five years ago, Jacqueline Gates and John Groskopf were strangers; they would soon discover they shared a rare similarity that would connect them forever.

On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in combination with lenalidomide (REVLIMID) for adult patients with relapsed or refractory diffuse large B-cell lymphoma…